Fundraising Fox
Ligand
NASDAQ: LGNDalso invests · investor profileLa Jolla, US · 3 known investors
Find your way into Ligand
Each arrow is one introduction. Sign up to fill in the first one.
Ask Greg Brown to introduce you to Todd Davis
You →Greg · together at Paul Capital Partners →Todd
Ask Jamie Chen to introduce you to Brook Byers
You →Jamie · together at Kleiner Perkins →Brook
Sign up to find every way you can get introduced to Ligand
- Your email: who you already know at Ligand, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Ligand team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Ligand is a royalty aggregator that finances late-stage clinical development and commercialization programs for biopharmaceutical companies. The company maintains a diversified portfolio of royalty assets across oncology, rare diseases, and other therapeutic areas, and licenses proprietary technology platforms to pharmaceutical manufacturers.
Founders & leadership
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$85.4M disclosed across 1 round · 2016
▶$85.4MraisedJan 2016 · 22 investors · PharmaceuticalsRule 506(c)
- MATTHEW W. FOEHRDirector
- JOHN L. HIGGINSExecutive Officer, Director
- JOHN LAMATTINADirector
- TODD DAVISDirector
- SUNIL PATELDirector
- JOHN KOZARICHDirector
- MATTHEW KORENBERGDirector
- DAVID M. KNOTTDirector
- JASON ARYEHDirector
- CHARLES S. BERKMANDirector
- STEPHEN SABBADirector
- MELANIE HERMANDirector
- Offering amount
- $85.4M
- Amount sold
- $85.4M
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Ligand went on to found or lead other companies.
Acquisitions · 1
Early investors' stakes continue via these dealsBiopharma royalty company acquired by Ligand, adding seven commercial products and more than 100 additional programs.
In the news
Frequently asked questions
- What does Ligand do?
- Ligand is a royalty aggregator that finances late-stage clinical development and commercialization programs for biopharmaceutical companies. The company maintains a diversified portfolio of royalty assets across oncology, rare diseases, and other therapeutic areas, and licenses proprietary technology platforms to pharmaceutical manufacturers.
- Who founded Ligand?
- Ligand was founded by Brook Byers.
- Who are Ligand's investors?
- Ligand's investors include Signet Healthcare Partners, Sofinnova Ventures, Venrock.
- How much funding has Ligand raised?
- Ligand has disclosed $85.4M raised across 1 round.
- Where is Ligand headquartered?
- Ligand is headquartered in La Jolla, US.